Washington, DC-based biopharmaceutical company developing and commercializing therapies for central nervous system disorders, dermatologic conditions, and rare diseases, with three FDA-approved products on market.
Company Info
Upcoming Milestones & Key Dates
FDA Rare Pediatric Disease Designation announcement
Bysanti NDA PDUFA action date expected
Clinical Development Pipeline
Recent News
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S (reported by PR Newswire)
Leadership Team
President and Chief Executive Officer
Chief Financial Officer
Careers & Job Openings